journal
MENU ▼
Read by QxMD icon Read
search

Critical Reviews in Oncology/hematology

journal
https://www.readbyqxmd.com/read/30396775/corrigendum-to-precision-medicine-in-alk-rearranged-nsclc-a-rapidly-evolving-scenario-crit-rev-oncol-hematol-122-february-2018-150-156
#1
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello
No abstract text is available yet for this article.
November 2, 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30401604/second-line-cabozantinib-versus-nivolumab-in-advanced-renal-cell-carcinoma-systematic-review-and-indirect-treatment-comparison
#2
REVIEW
Camillo Porta, Cezary Szczylik, Roman Casciano, Shuai Fu, Billy Amzal, Johanna Lister, Helene Karcher, Jie Meng, Monika Neumann, Jerome Dinet
BACKGROUND: Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved. METHODS: Two independent reviewers performed study selection, data extraction, and risk of bias assessment. Indirect treatment comparisons were carried out by directly assessing HR differences and statistical modeling of Kaplan-Meier curves from these two trials. RESULTS: Publications identified showed that no head-to-head comparisons had been carried out...
October 24, 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447931/continuous-therapy-in-standard-and-high-risk-newly-diagnosed-multiple-myeloma-a-pooled-analysis-of-2-phase-iii-trials
#3
REVIEW
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, Massimo Offidani, Roberto Ria, Maria Teresa Petrucci, Stefano Spada, Magda Marcatti, Lucio Catalano, Milena Gilestro, Tommasina Guglielmelli, Luca Baldini, Barbara Gamberi, Rita Rizzi, Giovanni De Sabbata, Nicola Di Renzo, Francesca Patriarca, Sara Pezzatti, Agostina Siniscalchi, Rossella Ribolla, Antonio Palumbo, Vittorio Montefusco, Arnon Nagler, Mario Boccadoro, Francesca Gay
BACKGROUND: Risk-adapted therapy is a common strategy in curable hematologic malignancies: standard-risk patients receive less intensive treatment, whereas high-risk patients require a more intensive approach. This model cannot be applied in multiple myeloma (MM), which is still incurable. Continuous treatment (CT) is a key strategy for MM treatment, since it improves duration of remission. However, the role of CT according to standard- or high-risk baseline prognosis remains an open question...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447930/the-role-of-endothelial-colony-forming-cells-in-kidney-cancer-s-pathogenesis-and-in-resistance-to-anti-vegfr-agents-and-mtor-inhibitors-a-speculative-review
#4
REVIEW
Valentina Poletto, Vittorio Rosti, Marco Biggiogera, Germano Guerra, Francesco Moccia, Camillo Porta
Renal cell carcinoma (RCC) is highly dependent on angiogenesis, due to the overactivation of the VHL/HIF/VEGF/VEGFRs axis; this justifies the marked sensitivity of this neoplasm to antiangiogenic agents which, however, ultimately fail to control tumor growth. RCC also frequently shows alterations in the mTOR signaling pathway, and mTOR inhibitors have shown a similar pattern of initial activity/late failure as pure antiangiogenic agents. Understanding mechanisms of resistance to these agents would be key to improve the outcome of our patients...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447929/antithrombotic-medication-in-cancer-associated-thrombocytopenia-current-evidence-and-knowledge-gaps
#5
REVIEW
A Leader, H Ten Cate, G Spectre, E A M Beckers, A Falanga
In cancer patients, antithrombotic medications (i.e. anticoagulation or antiplatelet therapy) are frequently prescribed for prior or new indications such as venous thromboembolism or stoke prevention in atrial fibrillation. Balancing the risks of bleeding and thrombosis during periods of thrombocytopenia represents a significant challenge. Management is informed mainly by expert opinion and several recent retrospective studies on venous thromboembolism. The main management options include no change, temporarily withholding antithrombotic therapy, reducing dose, changing the regimen, and increasing the platelet transfusion threshold...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447928/effect-of-long-term-aspirin-use-on-the-incidence-of-prostate-cancer-a-systematic-review-and-meta-analysis
#6
REVIEW
C M Sauer, D T Myran, C E Costentin, G Zwisler, T Safder, S Papatheodorou, L A Mucci
BACKGROUND: Previous studies found divergent effects of aspirin use on prostate cancer incidence, potentially due to studies with short durations of aspirin use and insufficient adjustment for screening. METHODS: A systematic review on the association between aspirin use ≥3 years and incident prostate cancer was performed in accordance with the PRISMA and MOOSE criteria. RESULTS: In the cohort studies, aspirin use for at least 3 years was associated with a lower incidence rate of prostate cancer (Odds ratio (OR) 0...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447927/magnetic-resonance-imaging-in-breast-cancer-management-in-the-context-of-neo-adjuvant-chemotherapy
#7
REVIEW
P Taourel, E Pages, I Millet, C Bourgier, P Rouanet, W Jacot, P Crochet, D Azria
This review discusses the clinical applications of magnetic resonance imaging (MRI) for the assessment of neo-adjuvant chemotherapy (NAC) indication, axillary lymph node status, preNAC cancer prognosis, early and intermediate response to NAC, and post-NAC residual disease in patients with breast cancer. Contrast-enhanced MRI with analysis of the tumor morphological features and qualitative enhancement kinetics must be considered as the standard method for pre-NAC breast cancer staging and post-NAC residual disease assessment...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447926/emerging-paradigms-in-the-treatment-of-liver-metastases-in-colorectal-cancer
#8
REVIEW
Abdulrahman Alhumaid, Zeyad AlYousef, Haafiz A Bakhsh, Saleh AlGhamdi, Mohammad Azhar Aziz
Efforts to combat colorectal cancer have benefited from improved screening and surveillance, which facilitates early detection. The survival rate associated with diagnosis at stage I is approximately 90%. However, progress in improving survival in metastatic colorectal cancer (mCRC) has been minimal. This review focuses on mCRC with special emphasis on the molecular aspects of liver metastases, which is one of the most frequently involved organ site. Better molecular evidence is required to guide the decisions for surgical and other interventions used in the clinical management of mCRC...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447925/performance-of-advanced-imaging-modalities-at-diagnosis-and-treatment-response-evaluation-of-patients-with-post-transplant-lymphoproliferative-disorder-a-systematic-review-and-meta-analysis
#9
REVIEW
F M Montes de Jesus, T C Kwee, M Nijland, X U Kahle, G Huls, R A J O Dierckx, T van Meerten, O Gheysens, D Dierickx, V Vergote, W Noordzij, A W J M Glaudemans
INTRODUCTION AND AIM: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ and hematopoietic stem cell transplantation, associated with significant morbidity and mortality. In this systematic review we evaluated the clinical performance of advanced imaging modalities at diagnosis and treatment response evaluation of PTLD patients after solid organ and hematopoietic stem cell transplantation. METHODS: We have carried out a literature search until December 15, 2017 using PubMed/Medline, Embase, "Web of Science" and Cochrane Library databases concerning the performance of computed tomography (CT), magnetic resonance imaging (MRI) and 18 F-flurodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) at diagnosis or treatment response evaluation of PTLD patients...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447924/the-role-of-cancer-testis-antigens-in-multiple-myeloma-pathogenesis-and-their-application-in-disease-monitoring-and-therapy
#10
REVIEW
Karen Shires, Teagan Van Wyk
A unique group of genes, encoding tumour associated antigens, known as the Cancer/Testis Antigens (CTAs), have been explored as novel markers of disease progression and as targets of immunotherapy in several cancers, including the haematological malignancy Multiple Myeloma (MM). This review aims to update the knowledge of CTA involvement in MM pathogenesis and how their potential as biomarkers for disease monitoring and targets of immunotherapy has been explored in the MM disease arena. Despite the initial promise of these antigens, their use as immunotherapy targets has not been successful, yet with a greater understanding of their role in disease pathogenesis they may still have a significant role to play as biomarkers of disease and therapeutic targets...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447923/direct-oral-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-cancer-patients-potential-for-drug-drug-interactions
#11
REVIEW
Hanno Riess, Paolo Prandoni, Sebastian Harder, Stephan Kreher, Rupert Bauersachs
Patients with cancer are at high risk of developing venous thromboembolism (VTE). Although the recommended low molecular weight heparins (LMWHs) are more effective than vitamin K antagonists in treating VTE in patients with cancer, they have limitations and contraindications. Direct oral anticoagulants (DOACs) circumvent some of these limitations. Here, DOAC use for VTE treatment in patients receiving anticancer therapy is reviewed, focusing on metabolic and elimination pathways, potential drug-drug interactions and practical considerations...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447922/a-rationale-multidisciplinary-approach-for-treatment-of-esophageal-and-gastroesophageal-junction-cancer-accurate-review-of-management-and-perspectives
#12
REVIEW
Antonio Chiappa, Bruno Andreoni, Renzo Dionigi, Lorenzo Spaggiari, Diego Foschi, Gianluca Polvani, Roberto Orecchia, Nicola Fazio, Gabriella Pravettoni, Maria Laura Cossu, Domenico Galetta, Marco Venturino, Carlo Ferrari, Lorenzo Macone, Cristiano Crosta, Bernardo Bonanni, Roberto Biffi
Cancer of the esophagus and of gastroesophageal junction can be cured, even if with lacking cure rate. Different approaches have been developed, mostly when carcinoma has loco-regional pattern. Multimodality therapy showed a survival rate superior than 10% if compared to a single approach. This is a systematic review, carried to assess the following matters: Which therapeutic opportunities are available? Who could benefit of them? Which adverse reactions could possibly verify? How can physicians definitely choose the proper strategy? Which is the role of surgery? We mean to give either General Practitioner or specialists clear and efficient updates about current treatment of this tumour, starting from physical examination...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447921/to-resect-or-not-to-resect-the-hamletic-dilemma-of-primary-tumor-resection-in-patients-with-asymptomatic-stage-iv-colorectal-cancer
#13
REVIEW
Fabio Gelsomino, Andrea Spallanzani, Giulia Orsi, Francesco Caputo, Chiara Santini, Stefano Cascinu
Primary tumor resection (PTR) in advanced asymptomatic colorectal cancer (CRC) has been a matter of intense debate for long time. With the advances in systemic treatments, this practice has decreased over the years, although it remains still pervasive. Although the removal of primary tumor has been extensively interrogated both in retrospective and prospective studies, it still remains a clinical conundrum. There are many arguments for and against PTR in CRC both from the preclinical and the clinical point of view...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447920/crosstalk-in-cancer-resistance-and-metastasis
#14
REVIEW
Saeed Norouzi, Mahmoud Gorgi Valokala, Fatemeh Mosaffa, Mohammad Reza Zirak, Parvin Zamani, Javad Behravan
The main obstacles that lead to clinical failure in cancer treatment are the development of resistant to chemotherapy and a rise in invasive characteristics in cancer tumor cells due to prolonged chemotherapeutic processes. Recent studies have revealed some evidence about the existence of a direct relationship between development of drug resistance and triggering of invasive capability in tumor cells. Therefore, devising and application of chemotherapeutic procedures that are not prone to the development of chemotherapy resistance are necessary...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447919/prevalence-of-pathogenic-variants-and-variants-of-unknown-significance-in-patients-at-high-risk-of-breast-cancer-a-systematic-review-and-meta-analysis-of-gene-panel-data
#15
REVIEW
C van Marcke, A Collard, M Vikkula, F P Duhoux
BACKGROUND: Gene-panels are used to assess predisposition to breast cancer by simultaneous testing of multiple susceptibility genes. This approach increases the identification of variants of unknown significance (VUS) that cannot be used in clinical decision-making. We performed a systematic review of published studies to calculate the prevalence of VUS and pathogenic variants (PV) in routinely tested breast cancer susceptibility genes in patients at high risk of breast cancer. METHODS: We comprehensively searched the literature using Medline through May 23, 2017 for studies conducting gene-panel testing on germline DNA of women with familial breast cancer and reporting on both PVs and VUSs...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447918/the-prognostic-value-of-the-systemic-inflammatory-response-in-randomised-clinical-trials-in-cancer-a-systematic-review
#16
REVIEW
Ross D Dolan, Barry J A Laird, Paul G Horgan, Donald C McMillan
BACKGROUND: The prognostic value of the systemic inflammatory response in cancer has been well established in observational studies. This review aims to examine and rationalise the evidence for the role of systemic inflammation based prognostic scores in randomised clinical trials. METHOD: An extensive literature review using targeted medical subject headings was carried out in the MEDLINE, EMBASE, and CDSR databases until January 2018. Titles were examined for relevance and after exclusions bibliographies were hand searched to identify additional trials...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447917/liver-toxicity-in-the-era-of-immune-checkpoint-inhibitors-a-practical-approach
#17
REVIEW
Carmen Belli, Massimo Zuin, Luca Mazzarella, Dario Trapani, Paolo D'Amico, Elena Guerini-Rocco, Bruno Achutti Duso, Giuseppe Curigliano
Immune checkpoint inhibitors have revolutionized the cancer treatment with an approved efficacy in different solid tumors and hematologic malignancies. These agents are increasing the indication in cancer treatment, but can be associated with serious immune-related adverse effects (IRAEs). Dermatologic and gastrointestinal toxicities are the most common IRAE followed by endocrinopathies with a different time of occurrence. Rarely cases of gastrointestinal toxicities are observed almost 2 years after initiation of the therapy...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447916/fertility-preserving-options-for-gynecologic-malignancies-a-review-of-current-understanding-and-future-directions
#18
REVIEW
Nathalie D McKenzie, Jessica A Kennard, Sarfraz Ahmad
Gynecological malignancies affect significant proportion of women in whom fertility preservation is a priority. Advancing reproductive technology and modern surgical techniques are changing the way young women with cancer are counseled regarding their fertility plans at time of cancer diagnosis. This review article provides the reader with fertility preserving updates in gynecologic malignancies as well as those with genetic predisposition for gynecologic malignancies. The different types of gynecologic malignancies including cervical, endometrial, and ovarian cancers and their unique obstacles are addressed separately...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447915/hormone-replacement-therapy-after-prophylactic-risk-reducing-salpingo-oophorectomy-and-breast-cancer-risk-in-brca1-and-brca2-mutation-carriers-a-meta-analysis
#19
REVIEW
C Marchetti, F De Felice, S Boccia, C Sassu, V Di Donato, G Perniola, I Palaia, M Monti, L Muzii, V Tombolini, P Benedetti Panici
BACKGROUND: Hormone replacement therapy (HRT) has been tested in women with BRCA1 and BRCA2 mutations who underwent risk-reducing salpingo-oophorectomy (RRSO), but its effect on breast cancer (BC) risk has never been appraised using meta-analysis comparison. We performed the first meta-analysis aimed to clarify whether HRT after RRSO could negatively impact on BC risk in women carriers of BRCA1 and BRCA2 mutations. METHODS AND MATERIAL: Pubmed and Scopus databases were searched to retrieve articles written in the English language...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30447914/polymorphisms-in-non-coding-rnas-and-risk-of-colorectal-cancer-a-systematic-review-and-meta-analysis
#20
REVIEW
Maryam Alidoust, Leila Hamzehzadeh, Mahdi Rivandi, Alireza Pasdar
Colorectal cancer (CRC) has been regarded as a common cancer due to its prevailing incidence in both males and females. Recently, non-coding RNAs used as biomarkers for screening, diagnosis and prognosis of different cancers have been under the focus of attention. As a result of this, the aim of this study was to systematically review articles that investigated the SNPs in genes related to microRNAs and long non-coding RNAs to assess the genetic susceptibility of colorectal cancer risk. The outcome is presented as the results of a meta-analysis...
December 2018: Critical Reviews in Oncology/hematology
journal
journal
20089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"